Regeneron Pharmaceuticals
REGN
638 hedge funds and large institutions have $26.9B invested in Regeneron Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 111 funds opening new positions, 239 increasing their positions, 200 reducing their positions, and 71 closing their positions.
56% more first-time investments, than exits
New positions opened: 111 | Existing positions closed: 71
20% more repeat investments, than reductions
Existing positions increased: 239 | Existing positions reduced: 200
5% more funds holding
Funds holding: 605 → 638 (+33)
3% less call options, than puts
Call options by funds: $1.23B | Put options by funds: $1.26B
1.59% less ownership
Funds ownership: 69.35% → 67.76% (-1.6%)
17% less capital invested
Capital invested by funds: $32.3B → $26.9B (-$5.46B)
31% less funds holding in top 10
Funds holding in top 10: 16 → 11 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$197M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$195M |
| 3 |
D.E. Shaw & Co
New York
|
+$181M |
| 4 |
Two Sigma Advisers
New York
|
+$154M |
| 5 |
Two Sigma Investments
New York
|
+$139M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$713M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$552M |
| 3 |
Jennison Associates
New York
|
-$455M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$269M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$211M |
REGN Hedge Fund Activity: Q4 2017 in Review
638 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q4 2017, worth a combined $26.9B — down 17% from $32.3B a quarter earlier.
Buyers outnumbered sellers: 111 funds opened new REGN positions and 71 closed out — a net gain of 40 holders — while 239 added to existing stakes and 200 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $197M. The largest seller was Capital World Investors, cutting an estimated $713M.
- 638 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q4 2017, up from 605 in Q3 2017.
- Funds reported $26.9B of Regeneron Pharmaceuticals stock for Q4 2017, down 17% quarter-over-quarter.
- 111 funds opened new Regeneron Pharmaceuticals positions in Q4 2017 and 71 closed out, a net change of +40 holders.
- The largest Regeneron Pharmaceuticals buyer in Q4 2017 was Renaissance Technologies, an estimated $197M added.
- The largest Regeneron Pharmaceuticals seller in Q4 2017 was Capital World Investors, an estimated $713M sold.
Based on aggregated 13F filings for Q4 2017.